{"entity":{"id":"bms","kind":"company","name":"Bristol Myers Squibb","aka":["Bristol-Myers Squibb","Juno Therapeutics","Mirati Therapeutics","Celgene","American Regent, Inc.","American Regent","YM BioSciences"],"tldr":"Pioneer of checkpoint inhibitors (Opdivo, Yervoy), now betting on the first successful bispecific ADC and alpha radiopharmaceuticals.","summary":"Bristol Myers Squibb, based in Princeton and listed as BMY, is the pioneer of checkpoint inhibitors with Opdivo and Yervoy, and it is now betting on the first successful bispecific antibody-drug conjugate and on alpha radiopharmaceuticals. Its portfolio spans nivolumab, ipilimumab and Opdualag, adagrasib from Mirati, the CAR-T products Breyanzi and Abecma, izalontamab brengitecan licensed from SystImmune for 8.4 billion dollars, actinium-225 DOTATATE from the 4.1 billion dollar RayzeBio purchase, and a PD-L1 by VEGF bispecific licensed from BioNTech for 11 billion dollars in 2025. Nuclide links it to the ten-year CheckMate 067 follow-up, CheckMate 649 and CheckMate 816 papers, to luspatercept, and to KRAS inhibitors and protein degradation. Whether its large bets on ADCs and radiopharmaceuticals pay off as the nivolumab franchise ages is the open question.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Bristol_Myers_Squibb","links":[{"label":"Official website","url":"https://www.bms.com"}],"tags":[],"related":["ac-225"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":["ryz101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Princeton, NJ","country":"US","companyType":"pharma","website":"https://www.bms.com","ticker":"BMY","investors":[],"funding":[]},"route":"/companies/bms/","neighbours":{"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"}],"drug":[{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/"}],"indication":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/"},{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/"},{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/"},{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"}],"bottleneck":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/"},{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/"}]}}